ABCD3 has been shown to be a biogenetic marker for malignancies such as human prostate cancer (Zhang et al., 2020b), ovarian cancer (Lima et al., 2015; Elsnerova et al., 2016), and non-small cell lung cancer (Tran, 2013) but has hardly been evaluated in glioma. This evidence concerns the gene ABCD3 and prostate carcinoma.